Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

This study tests whether adding a liver-directed chemotherapy technique called hepatic arterial infusion (HAI-FOLFOX) — delivering chemo directly into the liver's blood supply — to a drug called fruquintinib improves outcomes for people with colorectal cancer that has spread to the liver and stopped responding to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have colorectal cancer (bowel cancer) confirmed to have spread to the liver - Your cancer has stopped responding to standard chemotherapy regimens - Your liver tumors are the main site of disease (with no or very minimal spread elsewhere) **You may NOT be eligible if...** - Your cancer has spread significantly beyond the liver - You have serious liver, heart, or kidney problems - You have already received fruquintinib or regorafenib - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.